Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Major Plan to Recover Urgent and Emergency NHS Care Services
The NHS and the government will publish a new blueprint today to help recover urgent […]
Immusoft Awarded $8M in Funding from the California Institute for Regenerative Medicine (CIRM) for MPS I Clinical Program
Immusoft of CA, a wholly owned subsidiary of Immusoft, a clinical-stage cell therapy company dedicated […]
Legend Biotech Announces CARVYKTI Has Met Primary Endpoint in the Treatment of Relapsed and Refractory Multiple Myeloma
Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat […]
Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals
Quince Therapeutics, a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced […]
BioSenic appoints Yves Sagot as Independent Director
BioSenic, the clinical stage company specializing in serious autoimmune/inflammatory diseases and cell repair, today announces […]
Kinnate Biopharma Adds Global Business and Oncology Expertise to Board of Directors
Kinnate Biopharma, a clinical-stage precision oncology company, has announced that its board of directors has […]
Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication
Ascletis Pharma announces that the China National Medical Products Administration (NMPA) has approved the Investigational […]
New AI Tool Makes Speedy Gene Editing Possible
An artificial intelligence (AI) program may enable the first simple production of customizable proteins called […]
European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease
BioArctic AB‘s partner Eisai have announced that the European Medicines Agency (EMA) has accepted a […]
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more